Westpac Banking Corp increased its stake in Becton Dickinson and Co (NYSE:BDX) by 0.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 148,325 shares of the medical instruments supplier’s stock after purchasing an additional 1,266 shares during the quarter. Westpac Banking Corp owned about 0.05% of Becton Dickinson and worth $37,379,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of BDX. Comerica Securities Inc. lifted its stake in shares of Becton Dickinson and by 31.2% during the fourth quarter. Comerica Securities Inc. now owns 2,742 shares of the medical instruments supplier’s stock worth $618,000 after buying an additional 652 shares during the period. Dimensional Fund Advisors LP lifted its stake in shares of Becton Dickinson and by 10.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 525,300 shares of the medical instruments supplier’s stock worth $118,354,000 after buying an additional 49,738 shares during the period. Geode Capital Management LLC lifted its stake in shares of Becton Dickinson and by 7.5% during the fourth quarter. Geode Capital Management LLC now owns 3,208,583 shares of the medical instruments supplier’s stock worth $721,582,000 after buying an additional 223,215 shares during the period. First Citizens Bank & Trust Co. acquired a new stake in shares of Becton Dickinson and during the first quarter worth $271,000. Finally, Altman Advisors Inc. lifted its stake in shares of Becton Dickinson and by 1.9% during the first quarter. Altman Advisors Inc. now owns 8,846 shares of the medical instruments supplier’s stock worth $2,209,000 after buying an additional 169 shares during the period. 85.07% of the stock is owned by institutional investors and hedge funds.

A number of research analysts recently issued reports on the stock. Morgan Stanley boosted their target price on shares of Becton Dickinson and from $250.00 to $261.00 and gave the company an “equal weight” rating in a research report on Tuesday, July 16th. Barclays upgraded shares of Becton Dickinson and from an “equal weight” rating to an “overweight” rating and set a $266.00 target price for the company in a research report on Monday, May 13th. KeyCorp restated an “overweight” rating and set a $262.00 target price (down from $273.00) on shares of Becton Dickinson and in a research report on Friday, May 10th. BMO Capital Markets decreased their target price on shares of Becton Dickinson and from $272.00 to $270.00 and set a “market perform” rating for the company in a research report on Friday, May 10th. Finally, Piper Jaffray Companies decreased their target price on shares of Becton Dickinson and from $267.00 to $266.00 and set an “overweight” rating for the company in a research report on Tuesday, August 6th. Five research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $264.27.

BDX traded up $4.59 on Tuesday, reaching $253.75. The stock had a trading volume of 52,904 shares, compared to its average volume of 1,066,327. Becton Dickinson and Co has a 12-month low of $208.62 and a 12-month high of $265.87. The company has a current ratio of 1.09, a quick ratio of 0.67 and a debt-to-equity ratio of 0.84. The company has a 50-day moving average price of $251.93. The company has a market cap of $68.66 billion, a P/E ratio of 23.07, a P/E/G ratio of 1.85 and a beta of 1.11.

Becton Dickinson and (NYSE:BDX) last released its quarterly earnings data on Tuesday, August 6th. The medical instruments supplier reported $3.08 earnings per share for the quarter, beating analysts’ consensus estimates of $3.05 by $0.03. Becton Dickinson and had a net margin of 5.02% and a return on equity of 14.78%. The company had revenue of $4.35 billion during the quarter, compared to analysts’ expectations of $4.37 billion. During the same quarter in the previous year, the company earned $2.91 earnings per share. The firm’s revenue for the quarter was up 1.7% on a year-over-year basis. Analysts predict that Becton Dickinson and Co will post 11.68 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Monday, September 30th. Shareholders of record on Monday, September 9th will be issued a $0.77 dividend. The ex-dividend date of this dividend is Friday, September 6th. This represents a $3.08 dividend on an annualized basis and a yield of 1.21%. Becton Dickinson and’s payout ratio is 27.97%.

In other news, insider James C. Lim sold 1,929 shares of the business’s stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $252.01, for a total transaction of $486,127.29. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Patrick Kaltenbach sold 275 shares of the business’s stock in a transaction dated Tuesday, June 4th. The stock was sold at an average price of $235.00, for a total transaction of $64,625.00. Following the sale, the executive vice president now directly owns 16,482 shares of the company’s stock, valued at approximately $3,873,270. The disclosure for this sale can be found here. Insiders sold 24,529 shares of company stock valued at $5,836,116 in the last ninety days. 0.12% of the stock is owned by corporate insiders.

About Becton Dickinson and

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Featured Article: How Do You Make Money With Penny Stocks?

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.